Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)
Today's Latest Price: $78.28 USD
Updated Sep 29 2:51pm
Add HZNP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
HZNP Stock Summary
- HZNP has a higher market value than 89.15% of US stocks; more precisely, its current market capitalization is $16,448,697,758.
- The price/operating cash flow metric for Horizon Therapeutics Public Ltd Co is higher than 93.65% of stocks in our set with a positive cash flow.
- HZNP's price/sales ratio is 10.84; that's higher than the P/S ratio of 87.5% of US stocks.
- Stocks that are quantitatively similar to HZNP, based on their financial statements, market capitalization, and price volatility, are EXAS, AYX, AKAM, NTRA, and BL.
- Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.
HZNP Stock Price Chart Technical Analysis Charts
HZNP Price/Volume Stats
| Current price | $78.28 | 52-week high | $82.60 |
| Prev. close | $79.67 | 52-week low | $23.81 |
| Day low | $78.12 | Volume | 1,112,956 |
| Day high | $80.01 | Avg. volume | 2,227,837 |
| 50-day MA | $71.67 | Dividend yield | N/A |
| 200-day MA | $47.73 | Market Cap | 16.16B |
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $78.28 | $47.76 | -40% |
We started the process of determining a valid price forecast for Horizon Therapeutics Public Ltd Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 39.67%. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:
- The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.44 years is 0.45%; that's better than 75.06% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than just 17.65% of the free cash flow producing stocks we're observing.
- Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 115 -- greater than 97.73% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -41% |
| 1% | -41% |
| 2% | -40% |
| 3% | -39% |
| 4% | -39% |
| 5% | -38% |
EDAP, GSK, OSMT, PRGO, and MD can be thought of as valuation peers to HZNP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...